Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV

Abstract

As pharmacoeconomic evaluations for coverage decisions made by US public programs grows, the need for precise and consistent estimation of drug costs is warranted. Application of the proposed recommendations will allow researchers to include accurate and unbiased cost estimates in pharmacoeconomic evaluations.

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

“…The Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses Report is published in six parts based on analytic perspective. The next five articles in this issue of Value in Health report the issues and recommendations for pharmaceutical pricing from the different perspectives, including: 1) Societal [18]; 2) Managed care [19]; 3) Medicare, Medicaid, and other US Government Payers [20]; 4) Industry [21]; 5) European countries and other international country perspectives [22]. These perspective‐specific analyses are presented to provide guidance and recommendations on how to obtain and use appropriate drug cost measurements when conducting economic evaluations of health‐care interventions for different health‐care decision‐maker audiences.…”

Cost variation of antipsychotics in the public health system in Brazil: the implication for health resource use

“…However, conducting cost-effectiveness studies requires choosing valid unit costs and testing them for uncertainty, while ignoring such variability on drug costs may contribute to misleading decisions. ISPOR Task Force recommends as the best practice for measuring drug costs from health manager perspective the use of unit costs based on the price paid per drug unit (Mullins et al, 2010). However, these data are not easily obtainable because of confidentiality constraints or due to multiple sources involved in drug purchase.…”

Attributable Health Care Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium Difficile Infection in the United States

“…The total healthcare costs were calculated as the amount paid by primary and secondary insurers and by patients (ie, copayment and deductibles) across all claims (medical and pharmacy) during the 6 months after the index date. Healthcare costs were inflation-normalized to 2014 US dollars using the Consumer Price Index All Urban Consumers for Medical Care Services in accordance with the International Society for Pharmacoeconomics and Outcomes Research recommendations [27].…”